Remyelination In Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Remyelination is the phenomenon by which new myelin sheaths are generated around axons in the adult central nervous system (CNS). This follows the pathological loss of myelin in diseases like multiple sclerosis (MS). Remyelination can restore conduction properties to axons (thereby restoring neurological function) and is increasingly believed to exert a neuroprotective role on axons. Remyelination occurs in many MS lesions but becomes increasingly incomplete/inadequate and eventually fails in the majority of lesions and patients. Efforts to understand the causes for this failure of regeneration have fueled research into the biology of remyelination and the complex, interdependent cellular and molecular factors that regulate this process. Examination of the mechanisms of repair of experimental lesions has demonstrated that remyelination occurs in two major phases. The first consists of colonization of lesions by oligodendrocyte progenitor cells (OPCs), the second the differentiation of OPCs into myelinating oligodendrocytes that contact demyelinated axons to generate functional myelin sheaths. Several intracellular and extracellular molecules have been identified that mediate these two phases of repair. Theoretically, the repair of demyelinating lesions can be promoted by enhancing the intrinsic repair process (by providing one or more remyelination‐enhancing factors or via immunoglobulin therapy). Alternatively, endogenous repair can be bypassed by introducing myelinogenic cells into demyelinated areas; several cellular candidates have been identified that can mediate repair of experimental demyelinating lesions. Future challenges confronting therapeutic strategies to enhance remyelination will involve the translation of findings from basic science to clinical demyelinating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Secretory products of macrophages.
Nathan, C. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112815 · Cited by 2,615 · cited 1×
“The ad dition of periton eal macropha ges, in vitro , to fetal neu ron glia co cultures increases the synthe sis of myelin prot eins like MBP, and increa ses myelin deposition (Loughlin et al., 19 97; Nathan, 1987 ).”
BackgroundDisruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination
Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P. E., Griffiths, I. R., & Nave, K.-A. (2003) · Nature Genetics · doi:10.1038/ng1095 · Cited by 1,036 · cited 2×
“This is associated with a significant motor deficit that becomes manifest by about 4 months (Lappe-Siefke et al., 2003).”
BackgroundTNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 1×
“The authors concluded that remyelination failure could not be accounted for either by the absence of OPCs or their failure to generate oligodendrocytes, but instead suggested that demyelinated axons were themselves no longer receptive to remyelination (Chang et al., 2002).”
BackgroundAxonal Swellings and Degeneration in Mice Lacking the Major Proteolipid of Myelin
Griffiths, I., Klugmann, M., Anderson, T., Yool, D., Thomson, C., Schwab, M. H., Schneider, A., Zimmermann, F., McCulloch, M., Nadon, N., et al. (1998) · Science · doi:10.1126/science.280.5369.1610 · Cited by 889 · cited 1×
“In addition, absence of proteolipid protein (PLP), a major myelin protein, results in progressive axonal degeneration in rodents and humans (Garbern et al., 2002; Griffiths et al., 1998; Edgar et al., 2004).”
BackgroundInduction of myelination in the central nervous system by electrical activity
Demerens, C., Stankoff, B., Logak, M., Anglade, P., Allinquant, B., Couraud, F., Zalc, B., & Lubetzki, C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9887 · Cited by 678
Mechanisms of axon ensheathment and myelin growth
Sherman, D. L., & Brophy, P. J. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1743 · Cited by 668 · cited 2×
“Secure electrical conduction in axons is made possible by a defined organization of cellular processes and domain-specific ion channels at the nodes of Ranvier (reviewed by Sherman and Brophy, 2005).”
BackgroundHyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 1×
“Hyaluronan was found to inhibit remyelination of experimental demyelinating lesions; interestingly, OPCs were found to colonize such lesions but did not appear to mature into myelinating oligodendrocytes in areas of hyaluronan expression (Back et al., 2005).”
BackgroundWolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
Cited by
Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity
Nishiyama, A., Komitova, M., Suzuki, R., & Zhu, X. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2495 · Cited by 865
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Raeeszadeh-Sarmazdeh, M., Do, L., & Hritz, B. (2020) · Cells · doi:10.3390/cells9051313 · Cited by 324
CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination
Patel, J. R., McCandless, E. E., Dorsey, D., & Klein, R. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006301107 · Cited by 231
Zimmer, T. S., Broekaart, D. W. M., Gruber, V.-E., van Vliet, E. A., Mühlebner, A., & Aronica, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01028 · Cited by 48
“Because of the emerging evidence for a link between decreased myelin content and the development of neurological deficits, achieving remyelination of axons takes center stage in multiple sclerosis research, implying that it might be beneficial for mTORopathy patients as well (158, 159).”
The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia
Mecha, M., Yanguas-Casás, N., Feliú, A., Mestre, L., Carrillo-Salinas, F., Azcoitia, I., Yong, V. W., & Guaza, C. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.013 · Cited by 47
“…CNS, the loss of myelin is characteristic of demyelinating diseases like multiple sclerosis (MS), although it is often followed by a spontaneous process of remyelination, whereby oligodendrocyte progenitor cells (OPCs) differentiate and synthesize myelin to ensheath the exposed axons (Chari, 2007).”
Metadata
- Authors
- Chari, D. M.
- Venue
- International Review of Neurobiology
- Publisher
- Elsevier
- Published
- 2007
- Volume
- 79
- Pages
- 589-620
- ISSN
- 0074-7742 (ISSN-L)
- OpenAlex
- W1494387198
- Cited by
- 119
- References
- 27
- FWCI
- 15.84
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remyelination In Multiple Sclerosis. https://app.cochat.ai/papers/10.1016/s0074-7742(07)79026-8
- The paper
- Chari, D. M. (2007). Remyelination In Multiple Sclerosis. International Review of Neurobiology. https://doi.org/10.1016/s0074-7742(07)79026-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.